The recent wave of IgAN trials has reinforced galactose-deficient IgA1 (Gd-IgA1) as a mechanistic/pharmacodynamic biomarker, but not as a validated diagnostic or monitoring test. Agents targeting "hit 1" of the four-hit pathogenesis model consistently and rapidly lower serum Gd-IgA1: atacicept (ORIGIN 3), sibeprenlimab (VISIONARY/ENVISION), telitacicept, nefecon, and povetacicept all reduce circulating Gd-IgA1 alongside meaningful proteinuria reductions. Nonetheless, KDIGO 2025 states that urine protein excretion remains the only validated early biomarker guiding clinical decisions, and full drug approval is conditioned on the 24-month eGFR slope rather than Gd-IgA1 change. Outside trials, Gd-IgA1's diagnostic and prognostic performance is only moderate and confounded by assay heterogeneity (lectin vs. KM55 vs.glycopeptide LC-MS); it does not reliably separate IgAN from IgA vasculitis, though the Gd-IgA1/C3 ratio shows independent prognostic promise.
A key mechanistic caveat is that BAFF/APRIL blockade suppresses immunoglobulin production broadly, so the Gd-IgA1 fall largely parallels the decline in total IgA. In ORIGIN 3, week-36 reductions were ~68% Gd-IgA1, ~64% total IgA, ~36% IgG, and ~75% IgM — meaning the Gd-IgA1 drop is nearly indistinguishable from a class-wide immunoglobulin reduction. Meta-analyses confirm coordinated declines across IgG, IgA, and IgM. The only selectivity is at the isotype level: anti-APRIL monotherapy (sibeprenlimab) lowers IgA and IgM more than IgG (relative IgG-sparing), reflecting APRIL's role in mucosal IgA class-switching — but this is not true discrimination between the pathogenic glycoform and normally glycosylated IgA1. Trials generally report absolute changes rather than a Gd-IgA1:total-IgA ratio, so a glycoform-selective effect has not been demonstrated.
Finally, the Gd-IgA1 suppression is reversible. In the ENVISION follow-up, Gd-IgA1, total IgA1, and free APRIL all fell by roughly half at month 12 but rebounded toward baseline by month 16 (~4 months after the last dose), implyingthat indefinite therapy is likely needed. Notably, proteinuria reduction persisted somewhat longer than the biomarker rebound, particularly at higher doses. Because the effect is non-depleting, reversibility is considered a class effect, and Tonelli's NEJM editorial explicitly flags Gd-IgA1 rebound after discontinuation as an unresolved issue.
Overall, at this time, Gd-IgA1 functions as a real-time readout of target engagement rather than a validated, glycoform-specific disease monitor or a marker of durable disease modification.
Figure created using AI after input from text
No comments:
Post a Comment